ClinicalTrialsFinder

Tyrosine Kinase Inhibitor Clinical Trials in Wuhan, Hubei

1 recruitingWuhan, Hubei, China

Showing 1–1 of 1 trials

Recruiting
Phase 4

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

NSCLCLeptomeningeal MetastasisTyrosine Kinase Inhibitor+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07092202